Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04849273
Title A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Turning Point Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
Local Institution - 2104 Orange California 92868 United States Details
Local Institution - 2105 Aurora Colorado 80045 United States Details
Local Institution - 2106 Boston Massachusetts 02114-2696 United States Details
Local Institution - 2108 Boston Massachusetts 02215 United States Details
Local Institution - 2103 Hackensack New Jersey 07601 United States Details
Local Institution - 2107 Nashville Tennessee 37203 United States Details
Local Institution - 2102 Fairfax Virginia 22031-4629 United States Details
Local Institution - 6102 Blacktown New South Wales 2148 Australia Details
Local Institution - 6103 Heidelberg Victoria 3084 Australia Details
Local Institution - 6104 Melbourne Victoria 3000 Australia Details
Local Institution - 6101 Nedlands Western Australia 6009 Australia Details
Local Institution - 6303 Seoul Seoul-teukbyeolsi 05505 Korea, Republic of Details
Local Institution - 6301 Seoul 03722 Korea, Republic of Details
Local Institution - 6302 Seoul 06351 Korea, Republic of Details
Local Institution - 6304 Seoul 110-744 Korea, Republic of Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field